Prospective Validation of the OHI Index
A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index
Meir Medical Center
300 participants
Mar 3, 2021
OBSERVATIONAL
Conditions
Summary
Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
Eligibility
Inclusion Criteria2
- Patients with hematologic malignancies
- At least 18 years old
Exclusion Criteria1
- Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05882175